+ Access to medicine

Submission on the proposed methodology for international benchmarking of medicine prices

The proposed Methodology for International Benchmarking of Prices of Medicines and Scheduled Substances in South Africa seeks to introduce an addition to the state’s regulatory tools used to ensure that medicines are appropriately priced in South Africa. As a public interest law centre that seeks to influence, develop and use the law to protect, promote and advance human rights, SECTION27 welcomes the publication of the proposed methodology and this opportunity to make further submissions to the Department of Health (DoH).

Proposed EU economic partnership raises concerns about medicines access

After stalling for some time, negotiations for an economic partnership agreement (EPA) between the European Union (EU) on the one hand and the Southern African Customs Union (SACU), Mozambique and Angola on the other have recently restarted. According to an article published in Business Day on 10 February 2011, Xavier Carim – Deputy Director-General for international trade at the Department of Trade and Industry – is reported to have indicated that the EPA “should strike a balance between the levels of market access, regional harmonisation of rules, customs co-operation and safety, enforcement of intellectual property laws, competition, investment and procurement.”

SECTION27, TAC and MSF South Africa call on the EU and India to stop the threats to people’s lives

The Treatment Action Campaign (TAC), SECTION27 and Médecins Sans Frontières / Doctors Without Borders (MSF) South Africa voice support for their partners across the world opposing provisions in a proposed free trade agreement (FTA) between India and the European Union (EU) that threaten the sustainable supply of affordable medicines to millions of people in the developing world.

ESR Review: Regulating private power in health

by Jonathan Berger and Adila Hassim

On 28 July 2010, Ebersohn AJ of the North Gauteng High Court reviewed and set aside regulations purportedly made in terms of section 90(1)(u) and (v) of the National Health Act 61 of 2003 (NHA). As a result of this judgment, the Regulations Relating to the Obtainment of Information and the Process of Determination and Publication of the Reference Price List (the Regulations) and all related acts – including the determination and publication of the annual national health reference price list (NHRPL) – are now invalid.